OncoVista: Making Cancer Therapy Personal.

“The real breakthrough will come when such blood tests become sophisticated enough to reveal how tumors are changing over time, rather than simply spotting that they have come back. That should truly revolutionize cancer treatment, enabling the most effective combinations of drugs to be tailored to individual patients - and without the need for painful tissue biopsies.”

New Scientist: February 2010

That breakthrough is here.

Texas-based OncoVista (OTCBB: OVIT) is a high-growth theragnostic (the fusion of therapeutic and diagnostic medicine for individual patients) company that uses specific biomarkers to detect metastatic tumors, and to develop personalized, efficacious cancer treatments.

A theragnostic profile is a composite of various biomarker tests that characterize an individual patient’s specific therapeutic needs and her/his drug treatment outcome.

Circulating tumor cells (CTCs) are cells that circulate in the bloodstream. CTCs may constitute seeds for subsequent growth of additional tumors (metastasis) in different tissues.

CTC’s express biomarkers, which:

• Provide prognostic/predictive value for disease outcome and response to therapy
• Allow stratification of patients for enrollment in clinical trials based on drug target
• Enable monitoring of patient response to therapy
Allow profiling of metastatic disease which is otherwise difficult to access

OncoVista uses CTC analytical technology to acquire and develop personalized drug therapeutics that target cancer patients expressing particular biomarkers.

Biomarker targeted drugs (companion diagnostics) are the core business of OncoVista. The Company is not only capable of following the molecular signature of the metastatic tumor but also quantitate the over-expression of the biomarker in the patients. These indications allow fast and efficient development of highly efficacious and safe new targeted drugs.  

With its ability to detect biomarkers correlated with a high likelihood of response to a particular treatment, the company can acquire drugs that have a disproportionately high value to OncoVista and its shareholders.